MEDITECH(603990)2025-04-29 16:45Revenue Performance - Revenue for Q1 2025 was CNY 63,339,962.76, a decrease of 43.13% compared to CNY 111,382,482.48 in the same period last year[4] - Total revenue for Q1 2025 was CNY 63,339,962.76, a decrease of 43.1% compared to CNY 111,382,482.48 in Q1 2024[16] - Total operating costs for Q1 2025 were CNY 62,600,628.73, down 66.7% from CNY 187,332,029.36 in Q1 2024[16] Profitability - Net profit attributable to shareholders increased by 138.55% to CNY 23,595,895.17 from CNY 9,891,496.09 year-on-year[4] - Net profit for Q1 2025 reached CNY 24,879,667.86, compared to CNY 10,697,584.09 in Q1 2024, representing an increase of 132.5%[17] - Basic and diluted earnings per share rose to CNY 0.08, reflecting a 166.67% increase from CNY 0.03 in the previous year[4] - Basic and diluted earnings per share for Q1 2025 were both CNY 0.08, up from CNY 0.03 in Q1 2024[17] Cash Flow - The net cash flow from operating activities improved significantly, with a net outflow of CNY 17,526,663.30 compared to CNY 49,777,576.25 in the same period last year[4] - Cash inflow from operating activities for Q1 2025 was 177,134,783.83 in Q1 2024[19] - Net cash flow from operating activities was -49,777,576.25 in the previous year[20] - Cash inflow from investment activities totaled 110,285,578.84 in Q1 2024[20] - Net cash flow from investment activities was 202,907,913.28 in the same quarter last year[20] - Cash inflow from financing activities was 422,050,000.00 in Q1 2024[20] - Net cash flow from financing activities was -110,329,154.84 in the previous year[20] - The net increase in cash and cash equivalents for Q1 2025 was 142,356,334.69 in Q1 2024[21] - The ending balance of cash and cash equivalents was 270,573,241.18 in the previous year[21] Assets and Liabilities - Total assets decreased by 60.25% to CNY 1,257,717,677.11 from CNY 3,164,052,059.39 at the end of the previous year[5] - Total assets decreased to CNY 1,257,717,677.11 as of March 31, 2025, down from CNY 3,164,052,059.39 at the end of 2024[13] - Total liabilities decreased to CNY 428,139,147.95 as of March 31, 2025, compared to CNY 2,359,264,396.45 at the end of 2024[14] Operational Efficiency - The weighted average return on equity improved to 2.91%, an increase of 2.01 percentage points from 0.90%[5] - The company reported a significant reduction in research and development expenses to CNY 6,851,435.86 in Q1 2025 from CNY 15,448,941.63 in Q1 2024, a decrease of 55.7%[16] - The company is focusing on improving operational efficiency and reducing costs in response to the significant decline in revenue[16] Business Strategy - The company successfully exited the photovoltaic business in January 2025, which significantly improved profitability in its core medical business[7] - The company reported a significant reduction in cash outflows related to operating activities following the disposal of the photovoltaic subsidiary[7] - The company has ongoing projects in data resource development, with capitalized development expenditures of CNY 107,931,887.36 as of March 31, 2025[12] - The company has not disclosed any new product developments or market expansion strategies in this report[11] Accounting Standards - The company did not apply new accounting standards for the year 2025[22]